10-Q 1 ltho10q.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ----------------- FORM 10Q ----------------- (Mark One) [ X ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period end September 30, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to ___________ Commission file number: 000-50294 LEGACY TECHNOLOGY HOLDINGS, INC. -------------------------------- (Exact name of registrant as specified in its charter) Colorado 84-1426725 -------- ---------- (State of Incorporation) (IRS Employer ID Number) 7609 Ralston Road, Arvada, Colorado 80002 ----------------------------------------- (Address of principal executive offices) 303-422-8127 ------------ (Registrant's Telephone number) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 for Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [] Indicate by check mark whether the registrant is a large accelerated file, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X] (Do not check if a smaller reporting company) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X] Indicate the number of share outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of March 13, 2013, there were 5,731,732 shares of the registrant's common stock issued and outstanding.

PART I - FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) Page ---- Balance Sheets -~~June~~September 30, 2013 and December 31, 2012 (Audited) 1 Statements of Operations - Three and ~~Six~~Nine months ended ~~June~~September 30, 2013 and 2012 and From May 8, 2008 (Inception) to ~~June~~September 30, 2013 2 Statements of Changes in Shareholders' Deficit - From May 8, 2008 (Inception) to ~~June~~September 30, 2013 3 ~~- 4~~ Statements of Cash Flows - ~~Six~~Nine months ended ~~June~~September 30, 2013 and 2012 and From May 8, 2008 (Inception) to ~~June~~September 30, 2013 4 - 5 Notes to the Financial Statements 6 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 1315 Item 3. Quantitative and Qualitative Disclosures About Market Risk - Not Applicable 1618 Item 4. Controls and Procedures 1618 PART II - OTHER INFORMATION Item 1. Legal Proceedings -Not Applicable 1719 Item 1A. Risk Factors - Not Applicable 1719 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 1720 -Not Applicable Item 3. Defaults Upon Senior Securities - Not Applicable 1720 Item 4. Mine and Safety Disclosures 1720 Item 5. Other Information - Not Applicable 1720 Item 6. Exhibits 1821 SIGNATURES 1922

PART I ITEM 1. FINANCIAL STATEMENTS

LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED BALANCE SHEETS (Unaudited) ~~June~~September 30, December 31, 2013 2012 ----------------- ----------------- Assets Current Assets Cash $ ~~152~~1,883 $ 70 ----------------- ----------------- Total Assets, ~~all~~All ~~current~~Current Assets $ ~~152~~1,883 $ 70 ================= ================= Liabilities and Stockholders' Deficit Current liabilities Accounts payable $ ~~302~~329,~~007~~203 $ 325,229 Accrued expenses ~~859~~894,~~559~~997 802,269 Advances payable 4850,~~956~~004 68,956 Notes payable 31,632 31,632 Convertible notes payable 699,000 630,000 ----------------- ----------------- Total Current Liabilities 12,~~941~~004,~~154~~836 1,858,086 ----------------- ----------------- Convertible notes payable, long term 14,075 - ----------------- ----------------- Total Liabilities 2,018,911 1,858,086 Stockholders' Deficit Common stock, $0.0001 par value; 100,000,000 shares ~~373~~2,826 373 authorized; 328,258,860 shares issued and 5,731,772 shares issued issued and outstanding at ~~June~~September 30, 2013 and 3,731,772 shares issued and outstanding at December 31, 2012, ~~respectively~~ Additional paid-in capital 3,082,583 (1,~~094~~163,027) Common shares in Escrow (13,~~163~~379,~~027~~063) - Deficit accumulated during the development stage (~~847~~1,~~348~~723,374) (695,362) ----------------- ----------------- Total Stockholders' Deficit (12,~~941~~017,~~002~~028) (1,858,016) ----------------- ----------------- Total Liabilities and Stockholders' Deficit $ ~~152~~1,883 $ 70 ================= ================= See the accompanying notes to these consolidated financial statements.

LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended For the ~~Six~~Nine Months Ended May 8, 2008 ~~March~~September 3130, ~~June~~September 30, (Inception) to 2013 2012 2013 2012 ~~March~~September 3130, 2013 --------------------------- --------------------------- ------------------ Revenue: Sales $ - $ - $ - $ - $ - --------------------------- --------------------------- ------------------ Operational expenses: General and administrative 19842,~~762~~514 1814,~~927~~675 25868,~~695~~209 3550,~~584~~259 ~~288~~1,~~632~~131,146 --------------------------- --------------------------- ------------------ Total operational expenses 19842,~~762~~514 1814,~~927~~675 25868,~~695~~209 3550,~~584~~259 ~~288~~1,~~632~~131,146 --------------------------- --------------------------- ------------------ Loss from operations (19842,~~762~~514) (1814,~~927~~675) (25868,~~695~~209) (3550,~~584~~259) (~~288~~1,~~632~~131,146) --------------------------- --------------------------- ------------------ Other income (expense): Gain on debt relief - - - - 68,005 Finance cost of convertible notes -(14,075) - (6973,~~000~~075) - (6973,~~000~~075) Interest expense (29,~~423~~437) (28,~~047~~316) (5786,~~291~~728) (5584,~~824~~140) (~~557~~587,~~721~~158) --------------------------- --------------------------- ------------------ Total other expense (2943,~~423~~512) (28,~~047~~316) (~~126~~159,~~291~~803) (5584,~~824~~140) (~~558~~592,~~716~~228) --------------------------- --------------------------- ------------------ Net Loss $ (49886,~~185~~026) $ (4642,~~974~~991) $ (~~151~~1,~~986~~028,012) $ (91134,~~408~~399) $ (~~847~~1,~~348~~723,374) =========================== =========================== ================== Per share information Net (loss) per common share Basic $ (0.0104) $ (0.01) $ (0.0409) $ (0.0203) Fully diluted (0.0104) (0.01) (0.0409) (0.0203) --------------------------- --------------------------- Weighted average number of common stock outstanding 34,~~731~~956,~~772~~070 3,731,772 34,~~731~~144,~~772~~356 3,731,772 ~~---------------------------~~=========================== ~~---------------------------~~=========================== See the accompanying notes to these consolidated financial statements.

LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Additional Common Stock paid-in Number of shares Amount Capital ------------------- ----------------- ----------------- - Balances at December 31, 2006* - $ - $ - Net income (loss) for the year - - - ------------------- -------------- ----------------- Balances at December 31, 2007* - - - Issuance of Founders common stock - cash 4,800,000 480 5,120 Issuance of Founders common stock - services 4,200,000 420 3,780 Stock issued for Net Liabilities - reverse merger 1,007,003 101 (1,197,555) Capital contribution - related party - - 25,000 Net income (loss) for the year - - - ------------------- -------------- ----------------- Balance as of December 31, 2008* 10,007,003 1,001 (1,163,655) ------------------- -------------- -------------------- Cancellation of shares (6,275,231) (628) 628 Net income (loss) for the year - - - ------------------- -------------- ----------------- Balance as of December 31, 2009 3,731,772 373 (1,163,027) ------------------- -------------- ----------------- Net income (loss) for the year - - - ------------------- -------------- ----------------- Balance as of December 31, 2010 3,731,772 373 (1,163,027) ------------------- -------------- ----------------- Net income (loss) for the year - - - ------------------- -------------- ----------------- Balance as of December 31, 2011 3,731,772 373 (1,163,027) ------------------- -------------- ----------------- Net income (loss) for the year - - - ------------------- -------------- ----------------- Balance as of December 31, 2012 3,731,772 373 (1,163,027) ------------------- -------------- ----------------- Issuance of shares for services 2,000,000 200 799,800 Issuance of common shares for acquisition in escrow 22,527,088 2,253 3,376,810 Convertible Promissory Note Discount - - 69,000 Net income (loss) for the period - - - ------------------- -------------- ----------------- Balance as of ~~March~~September 3130, 2013 328,~~731~~258,~~772~~860 $ ~~373~~2,826 $(1 3,~~094~~082,~~027)~~583 =================== ============== ================= * As restated for reverse merger on July 18, 2008 See the accompanying notes to these consolidated financial statements. 3

(continued) LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Deficit accum Common Shares During in Development Escrow Stage Totals ----------------- ---------------- ---------------- Balances at December 31, 2006* $ - $ - $ - Net income (loss) for the year - - - ----------------- ---------------- ---------------- Balances at December 31, 2007* - - - Issuance of Founders common stock - cash - - 5,600 Issuance of Founders common stock - services - - 4,200 Stock issued for Net Liabilities - reverse merger - - (1,197,454) Capital contribution - related party - - 25,000 Net income (loss) for the year - (98,782) (98,782) ----------------- ---------------- ---------------- Balance as of December 31, 2008* - (98,782) (1,261,436) ----------------- ---------------- ---------------- Cancellation of shares - - - Net income (loss) for the year - (155,673) (155,673) ----------------- ---------------- ---------------- Balance as of December 31, 2009 - (254,455) (1,417,109) ----------------- ---------------- ---------------- - Net income (loss) for the year - (125,970) (125,970) ----------------- ---------------- ---------------- Balance as of December 31, 2010 - (380,425) (1,543,079) ----------------- ---------------- ---------------- Net income (loss) for the year - (137,719) (137,719) ----------------- ---------------- ---------------- Balance as of December 31, 2011 - (518,144) (1,680,798) ----------------- ---------------- ---------------- Net income (loss) for the year - (177,218) (177,218) ----------------- ---------------- ---------------- Balance as of December 31, 2012 - (695,362) (1,858,016) ----------------- ---------------- ---------------- Issuance of shares for services - - 800,000 Issuance of common shares for acquisition in escrow (3,379,063) - - Convertible Promissory Note Discount - - 69,000 Net income (loss) for the period - (~~151~~1,~~986~~028,012) (~~151~~1,~~986~~028,012) ----------------- ---------------- ---------------- Balance as of ~~March~~September 3130, 2013 $ (~~847~~3,~~348~~379,063) $ (1,~~941~~723,~~002~~374) $ (2,017,028) ================= ================ ================ * As restated for reverse merger on July 18, 2008 See the accompanying notes to these consolidated financial statements.

LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) May 8, 2008 For the ~~Six~~Nine Months Ended (Inception) to ~~June~~September 30, ~~March~~September 3130, 2013 2012 2013 --------------- --------------- --------------- Cash Flows from Operating Activities: Net Loss $ (~~151~~1,~~986~~028,012) $ (91134,~~408~~399) $ (~~847~~1,~~348~~723,374) Adjustment to net loss for non-cash items: Finance cost of convertible promissory notes 6973,~~000~~075 69- 73,~~000~~075 ~~Adjustments~~Stock toissued ~~reconcile~~for ~~net~~services ~~loss~~800,000 to- ~~net~~800,000 ~~cash used in operating activities from continuing operations:~~ Gain on debt relief - - (68,005) Compensatory Stock issuance - - 4,200 Adjustments to reconcile net loss to net cash used in operating activities from continuing operations: Changes in operating assets and liabilities: Increase in Accounts Payable and Accrued Liabilities 3491,~~068~~505 86128,~~378~~619 ~~689~~746,~~250~~687 --------------- --------------- --------------- Net Cash Provided (Used) by Operating Activities (4863,~~918~~432) (5,~~030~~780) (~~152~~167,~~903~~417) --------------- --------------- --------------- Cash Flows from Investing Activities: Net Cash Provided by Investing Activities - - - --------------- --------------- --------------- Cash Flows from Financing Activities: Capital contribution for related parties - - 25,000 Sale of common stock - - 5,600 Funds from convertible promissory notes 4454,000 4454,000 Proceeds from advance payables 511,~~000~~175 5,~~100~~850 7380,~~956~~131 --------------- --------------- --------------- Net Cash Provided (used) by Financing Activities 4965,~~000~~175 5,~~100~~850 ~~148~~164,~~556~~731 --------------- --------------- --------------- Net Increase in Cash 821,743 70 (42,~~347~~686) Cash and Cash Equivalents - Beginning of Period 70 - 4,499 --------------- --------------- --------------- Cash and Cash Equivalents - End of Period $ ~~152~~1,813 $ - $ ~~152~~1,813 =============== =============== =============== SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest expense $ - - - =============== =============== =============== Cash paid for income taxes $ - - - =============== =============== =============== SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Common shares issued for services $ 800,000 - - =============== =============== =============== Common shares issued in reverse merger $ - $ - $ (1,197,454) =============== =============== =============== See the accompanying notes to these consolidated financial statements.

5 LEGACY TECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY (A Development Stage Enterprises) Notes to the Consolidated Financial Statements For the Nine Months Ended September 30, 2013 (Unaudited) NOTE 1. Business, Basis of Presentation and Significant Accounting Policies: Business: Legacy Technology Holdings, Inc. (the "Company" and/or "Legacy") was incorporated in Colorado in January, 1997. The Company was originally named Life USA, Inc. On May 20, 2008, the Company changed its name to Legacy Technology Holdings, Inc. by filing an amendment to its Article of Incorporation. The Company was organized to engage in any activity or business not in conflict with the laws of the State of Colorado or of the United States of America. As a result of the name change, the Company's trading symbol on the Over-the-Counter Bulletin Board was changed to "LTHO". Neuro Nutrition, the Company's wholly owned subsidiary, was incorporated on July 23, 2004 in the State of Colorado, and has no operational activities. World Peace, the Company's wholly owned subsidiary was incorporated in the State of Colorado on May 8, 2008 and has had no operational activities during the nine months ended September 30, 2013 nor during the year ended December 31, 2012. Reorganization and Share Exchange: On April 4, 2013, the Company entered into a Plan and Agreement of Reorganization and Share Exchange Agreement ("the Agreement") with Genomic Integrated Wellness Systems, Inc. ("GIWS") and GIWS's sole shareholder, Charles Youngren. On November 21, 2013, the Agreement was amended to include GIWS's additional shareholder. The amended Agreement provides for the Company to issue 22,527,088 shares of its restricted common stock to be exchanged for 100% of the issued and outstanding equity of GIWS, making the Company the sole shareholder of GIWS. As a result of the issuance, the majority shareholder of GIWS, Charles Youngren, will hold 74.76% of the issued and outstanding common stock of the Company, post-acquisition. Closing of the acquisition is contingent upon the delivery of audited financial statements by GIWS. At the time of this filing, the transaction has not been closed. On September 28, 2013, the Company did issue the 22,527,088 shares of common stock in connection with the merger. The Company holds these shares in escrow until the closing of the acquisition and therefor does not count them in their issued and outstanding shares of common stock at September 30, 2013. The Company received audit financial statements on March 31, 2013 and has closed the transaction at that time. 6 Basis of Presentation: Development Stage Enterprise The Company has not earned any significant revenues from its limited operations. Accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise" Among the disclosures required by are that the Company's financial statements be identified as those of a development stage company, and that the statements of operation, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Legacy and its wholly-owned subsidiaries, Neuro Nutrition, Inc. and Legacy Technology Holdings (formerly World Peace Technologies, Inc.) All significant inter-company balances and transactions have been eliminated in consolidation. Significant Accounting Policies: Cash and Cash Equivalents The Company maintains the majority of its cash accounts at a commercial bank. The total cash balance is insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000 per commercial bank. As of September 30, 2013 and December 31, 2012, the Company had zero amounts in excess of the FDIC insured limits. For purposes of the statement of cash flows, the Company considers all cash and highly liquid investments with initial maturities of three months or less to be cash equivalents. Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates may be materially different from actual financial results. Significant estimates include the recoverability of long-lived assets and the collectability of accounts receivable. Revenue Recognition Revenue Recognition is recognized when earned. Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. 7 Net Loss per Share Basic net loss per common share is calculated by dividing the net loss applicable to common shares by the weighted average number of common and common equivalent shares outstanding during the period. For the nine and three months ended September 30, 2013 and 2012, there were no potential common equivalent shares used in the calculation of weighted average common shares outstanding as the effect would be anti-dilutive because of the net loss. Stock-Based Compensation The Company adopted the provisions of and accounts for stock-based compensation using an estimate of value in accordance with the fair value method. Under the fair value recognition provisions of this statement, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which generally is the vesting period. The Company elected the modified-prospective method, under which prior periods are not revised for comparative purposes. The valuation method applies to new grants and to grants that were outstanding as of the effective date and are subsequently modified. Fair Value of Financial Instruments The carrying amount of accounts payable, accrued expenses, convertible promissory notes are considered to be representative of their respective fair values because of the short-term nature of these financial instruments. Other Comprehensive Income The Company has no material components of other comprehensive income (loss) and accordingly, net loss is equal to comprehensive loss in all periods. Income Taxes Provision for income taxes represents actual or estimated amounts payable on tax return filings each year. Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets, and for operating loss and tax credit carry forwards. The change in deferred tax assets and liabilities for the period measures the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws on deferred tax assets and liabilities are reflected as adjustment to the tax provision or benefit in the period of enactment. Recent Accounting Pronouncements There were various other accounting standards and interpretations issued during the nine months ended September 30, 2013, none of which are expected to have a material impact on the Company's financial position, operations or cash flows. 8 NOTE 2. Going Concern: The Company's financial statements for the nine months ended September 30, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company reported a net loss of $1,028,012 for the nine months ended September 30, 2013, and an accumulated deficit of $1,723,374 as of September 30, 2013. At September 30, 2013, the Company had a working capital deficit of $2,002,953. The future success of the Company is likely dependent on its ability to attain additional capital, or to find an acquisition to add value to its present shareholders and ultimately, upon its ability to attain future profitable operations. There can be no assurance that the Company will be successful in obtaining such financing, or that it will attain positive cash flow from operations. Management believes that actions presently being taken to revise the Company's operating and financial requirements provide the opportunity for the Company to continue as a going concern. NOTE 3. Notes Payable: The Company's outstanding non-convertible notes payable on September 30, 2013 and December 31, 2012, consisted of: $ 15,080 Note Payable issued to an investor. Due upon demand. Interest rate is 8% 10,353 Note payable, issued to vendor. Due upon demand 6,199 Other notes payable -------- $ 31,632 Total notes payable outstanding on September 30, 2013 and December 31, 2012. ===== NOTE 4. Convertible Notes Payable: Convertible notes payable as of September 30, 2013 and December 31, 2012 consisted of the following: $ 50,000 Note payable 1, convertible into 151,515 shares with conversion feature expiring in May 2008, due September 30, 2006, incurring interest at 25%, attached to the note are 151,515 warrants exercisable at $0.625 per share, which expired in 2008. The note is secured by a subordinated pledge of inventory and accounts receivable. $ 25,000 Note payable 2, convertible into 50,000 shares of Neuro Nutrition, Inc. with conversion feature expiring at end 2007, due September 7, 2006, incurring interest at 10%. $ 50,000 Note payable 1, convertible into 151,515 shares with conversion feature expiring in May 2008, due September 30, 2006, incurring interest at 25%, attached to the note are 151,515 warrants exercisable at $0.625 per share, which expired in 2008. The note is secured by a subordinated pledge of inventory and accounts receivable. 9 $ 75,000 Note payable 4, convertible into 227,273 shares with conversion feature expiring in May 2008, due September 30, 2006, incurring interest at 25%, attached to the note are 227,273 warrants exercisable at $0.625 per share, which expired in 2008. The note is secured by a subordinated pledge of inventory and accounts receivable. $ 20,000 Note payable 5, convertible into 40,000 shares of Neuro Nutrition, Inc. anytime at Holder's option, due February 28, 2007, incurring interest at 20%,attached to the note are 40,000 warrants for Neuro Nutrition, Inc. common stock exercisable at $0.65 per share. $ 50,000 Note payable 6, convertible into 100,000 shares of Neuro Nutrition, Inc. anytime at Holder's option, due February 28, 2007, incurring interest at 20%, attached to the note are 100,000 warrants for Neuro Nutrition, Inc. common stock exercisable at $0.65 per share. $ 75,000 Note payable 7, convertible into 150,000 shares of Neuro Nutrition, Inc. with conversion feature expiring in May 2008, due May 27, 2006, incurring interest at 10%, attached to the note are 150,000 warrants for Neuro Nutrition, Inc. exercisable at $0.625 per share, which expired in 2008. $ 50,000 Note payable 8, convertible into 100,000 shares with conversion feature expiring in November 2008, due November 11, 2006, incurring interest at 10%, attached to the note are 200,000 warrants exercisable at $0.625 per share, which expired in 2008. $ 50,000 Note payable 8, convertible into 100,000 shares with conversion feature expiring in November 2008, due November 11, 2006, incurring interest at 10%, attached to the note are 200,000 warrants exercisable at $0.625 per share, which expired in 2008. $ 5,000 Note payable 10, convertible into 10,000 shares with conversion feature expiring in November 2008, due November 11, 2006, incurring interest at 10%, attached to the note are 20,000 warrants exercisable at $0.625 per share, which expired in 2008. $ 50,000 Note payable 11, convertible into 100,000 shares anytime at Holder's option, due December 7, 2006, incurring interest at 10%, attached to the note are 200,000 warrants exercisable at $0.625 per share, which expired in 2008. 10 $ 25,000 Note payable 12, convertible into 50,000 shares anytime at Holder's option, due February 20, 2007, incurring interest at 10%, attached to the note are 100,000 warrants exercisable at $0.75 per share, which expired in 2008. $ 5,000 Note payable 13, convertible into 10,000 shares anytime at Holder's option, due February 28, 2007, incurring interest at 10%, attached to the note are 20,000 warrants exercisable at $0.75 per share, which expired in 2008. $ 50,000 Note payable 14, convertible into 125,000 shares anytime at Holder's option, due September 12, 2006, incurring interest at 25%, attached to the note are 250,000 warrants exercisable at $0.75 per share, which expired in 2008. This note is secured by inventory and accounts receivable. $ 50,000 Note payable 15, convertible into 125,000 shares anytime at Holder's option, due September 12, 2006, incurring interest at 25%, attached to the note are 250,000 warrants exercisable at $0.75 per share, which expired in 2008. This note is secured by inventory and accounts receivable. -------- $630,000 Total Convertible notes payable. All these notes, with ======== the exception of notes 1, 3, 4, 14 and 15 are unsecured. As of September 30, 2013, all of the convertible notes described above are in default. In March 2013, the Company issued an unsecured convertible promissory note in exchange for cash of $44,000. In addition, the Company issued an unsecured convertible promissory note in exchange for already outstanding advances of $25,000. The convertible promissory notes have a term of 1 year, an interest rate of 8% per annum and provides for the conversion of the note into shares of the Company's common stock at $0.07 per share. The Company has recognized a finance cost of $69,000 in connection with the convertible promissory notes. NOTE 5. Convertible Note Payable, Long Term In September 30, 2013, the Company issued an unsecured convertible promissory note in exchange for cash of $10,000. The convertible promissory note has a term of 3 years, an interest rate of 8% per annum and provides for the conversion of the note into shares of the Company's common stock at $0.40 per share. The Company has recognized a finance cost of $14,075 in connection with the convertible promissory notes. NOTE 6. Stockholders' Equity (Deficit): Common Stock: In September 2013, the Company issued a total of 2,000,000 shares of its restricted common stock to existing shareholders and its sole officer and director for services. The shares were valued at a price of $0.40, the then market per share for an expense of $800,000. 11 On April 4, 2013, the Company entered into a Plan and Agreement of Reorganization and Share Exchange Agreement ("the Agreement") with Genomic Integrated Wellness Systems, Inc. ("GIWS") and GIWS's sole shareholder, Charles Youngren. On November 21, 2013, the Agreement was amended to provide to include GIWS's additional shareholder. The Amended Agreement provides for the Company to issue 22,527,088 shares of its restricted common stock to be exchanged for 100% of the issued and outstanding equity of GIWS, making the Company the sole shareholder of GIWS. Closing of the acquisition is contingent upon the delivery of audited financial statements by GIWS. On September 28, 2013, the Company did issue the 22,527,088 shares of common stock in connection with the anticipated closing of the merger. The Company holds these shares in escrow until the closing of the acquisition and therefor does not count them in their issued and outstanding shares of common stock at September 30, 2013. The shares at this time have booked at a price of $0.15 per share based upon the closing market price of April 30, 2013, the date of the Agreement. The Company received audit financial statements on March 31, 2014 and has closed the transaction at that time. Stock Options and Warrants: At September 30, 2013, the Company had stock option and warrant activity as described below. Non-employee stock options The Company accounts for non-employee stock options under ASC 718, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares. The Company's subsidiary Neuro Nutrition, Inc. at the beginning of 2010 had 140,000 common stock purchase warrants outstanding. The warrants are to be effectively granted for exercise upon conversion by the warrant holder of an accompanying note payable into common stock, which said note the holder can convert anytime at his option. The warrant holder has two years after effective grant date to exercise the warrants, at a price of $.625 per share. No Neuro Nutrition, Inc. warrants were exercised or expired during the three months ended, leaving a balance of 140,000 warrants at September 30, 2013. Employee stock options The Company accounts for employee stock options under ASC 718. Unless otherwise provided for, the Company covers option exercises by issuing new shares. There were no employee stock options issued or outstanding at September 30, 2013. NOTE 7. Taxes: The Company is subject to foreign and domestic income taxes. The Company has had no income, and therefore has paid no income tax. 12 Deferred income taxes arise from temporary timing differences in the recognition of income and expenses for financial reporting and tax purposes. The Company's deferred tax assets consist entirely of the benefit from net operating loss (NOL) carry-forwards. The NOL carry forwards expire in various years through 2030. The Company's deferred tax assets are offset by a valuation allowance due to the uncertainty of the realization of the NOL carry-forwards. NOL carry-forwards may be further limited by a change in company ownership and other provisions of the tax laws. The Company's deferred tax assets, valuation allowance, and change in valuation allowance are as follows: Estimated NOL Carry-forward Valuation Net Tax Period Ending benefit Allowance Benefit September 30, 2013 $347,421 $(347,421) - December 31, 2012 $139,072 $(139,072) - NOTE 8 - Legal Proceedings: In May 2008 a complaint was filed in the District Court for the County of Boulder, Colorado by product suppliers of the Company (the "Plaintiffs") seeking collection of trade accounts due in the approximate amount of $127,000 plus collection costs. Research of the account by Plaintiff's counsel effectively reduced this amount to approximately $64,000, which is included in the Company's balance sheet liabilities. The case is ongoing at the present time. NOTE 9 - Subsequent Events: Reorganization and Share Exchange: On April 4, 2013, the Company entered into a Plan and Agreement of Reorganization and Share Exchange Agreement ("the Agreement") with Genomic Integrated Wellness Systems, Inc. ("GIWS") and GIWS's sole shareholder, Charles Youngren. On November 21, 2013, the Agreement was amended to include GIWS's additional shareholder. The amended Agreement provides for the Company to issue 22,527,088 shares of its restricted common stock to be exchanged for 100% of the issued and outstanding equity of GIWS, making the Company the sole shareholder of GIWS. As a result of the issuance, the majority shareholder of GIWS, Charles Youngren, will hold 74.76% of the issued and outstanding common stock of the Company, post-acquisition. Closing of the acquisition is contingent upon the delivery of audited financial statements by GIWS. On September 28, 2013, the Company did issue the 22,527,088 shares of common stock in connection with the anticipated closing of the merger. The Company holds these shares in escrow until the closing of the acquisition and therefor does not count them in their issued and outstanding shares of common stock at September 30, 2013. The shares at this time have booked at a price of $0.15 per share based upon the closing market price of April 30, 2013, the date of the Agreement. 13 The Company received audit financial statements on March 31, 2013 and has closed the transaction at that time. The Company has evaluated it activities subsequent to September 30, 2013 and through the issuance of the financial statements and found no other reportable subsequent events. 14 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion should be read in conjunction with our unaudited financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward-looking statements. The independent registered public accounting firm's report on the Company's financial statements as of December 31, 2012, and for each of the years in the two-year period then ended, includes a "going concern" explanatory paragraph, that describes substantial doubt about the Company's ability to continue as a going concern. PLAN OF OPERATIONS ------------------ We had we had no revenues during the nine months ended September 30, 2013. We have minimal capital, minimal cash, and only our intangible assets consisting of our business plan, relationships and contacts. We are illiquid and need cash infusions from investors or shareholders to provide capital, or loans from any sources. The Company has focused its efforts, since July of 2009, has focused its efforts on the completion of its past due audits and the filing of its financial reports with the Securities and Exchange Commission (SEC). As we have come closer to the completion of such efforts, the Company has begun to focus its efforts on the development of operations through an acquisition. On April 4, 2013, the Company entered into a Plan and Agreement of Reorganization and Share Exchange Agreement ("the Agreement") with Genomic Integrated Wellness Systems, Inc. ("GIWS") and GIWS's sole shareholder, Charles Youngren. On November 21, 2013, the Agreement was amended to include GIWS's additional shareholder. The amended Agreement provides for the Company to issue 22,527,088 shares of its restricted common stock to be exchanged for 100% of the issued and outstanding equity of GIWS, making the Company the sole shareholder of GIWS. As a result of the issuance, the majority shareholder of GIWS, Charles Youngren, will hold 74.76% of the issued and outstanding common stock of the Company, post-acquisition. At the time of this filing, the transaction has not been closed. On September 25, 2013, the Company did issue the 22,527,088 shares of common stock in connection with the anticipated closing of the merger. The Company holds these shares in escrow until the closing of the acquisition and therefor does not count them in their issued and outstanding shares of common stock at September 30, 2013. The shares at this time have booked at a price of $0.15 per share based upon the closing market price of April 30, 2013, the date of the Agreement. 15 The Company received audit financial statements on March 31, 2013 and has closed the transaction at that time. In addition, at closing, the existing officers of the Company will resign and new officers will be appointed by GIWS's sole shareholder. Mr. Youngren will be appointed the Chief Operating Officer and a director of the Company. In addition, as, the sole shareholder of GIWS, Mr. Youngren will have the ability to appoint two new directors to the Company's Board of Directors. GIWS was incorporated on November 15, 2012 in the state of Colorado, but has operations in Hawaii. GIWS was formed in order to develop and commercialize a web-based genomic preventative medicine solution using sophisticated and proprietary algorithms to analyze data, on individual patient lifestyle factors such as biometrics, diet, pharmaceuticals, endocrine and blood tests, and genetic markers. The aggregation of this Patient data in a Data Warehouse will facilitate analysis via a variety of Machine Learning Algorithms. Discovery of Genetic Marker patterns, endocrine and blood analysis detected trends, and associations with individual Patient factors can facilitate customized Individual Patient Preventative Medicine solutions by health professionals to mitigate the expression of undesirable Genetic characteristics and to enhance the expression of desirable Genetic characteristics. We will need substantial additional capital to support our proposed business acquisition. We have no revenues. We have no committed source for any funds as of date here. No representation is made that any funds will be available when needed. In the event funds cannot be raised when needed, we may not be able to carry out our business plan, may never achieve sales or royalty income, and could fail in business as a result of these uncertainties. RESULTS OF OPERATIONS --------------------- For the Three Months Ended September 30, 2013 Compared to the Three Months Ended September 30, 2012 During the three months ended September 30, 2013 and 2012, we did not recognize any revenues from our operations. We do not expect to recognize revenues in the near future, as we work to complete our proposed acquisition with GIWS, discussed above. During the three months ended September 30, 2013, we incurred general and administrative expenses of $842,514 compared to $14,675 during the nine months ended September 30, 2012. The increase of $827,839 was a result of an increase of $815,250 in consulting expenses combined with a $12,619 in legal expenses. These increases were a result of increased administrative activity in connection with the GIWS acquisition, including a $8000,000 non-cash expense for a total of 2,000,000 shares of common stock issued to shareholders and the Company's sole officer and director in connection with their acquisition efforts. During the three months ended September 30, 2013, we incurred a net loss of $886,026, compared to $42,991 during the three months ended September 30, 2012. The increase of $843,035 is a result of the $815,250 increase in general and administrative expenses, combined with the $14,075 increase in finance costs and the $1,121 increase in interest expenses resulting from the $79,000 increase in convertible promissory notes during the nine months ended September 30, 2013. 16 For the Nine Months Ended September 30, 2013 Compared to the Nine Months Ended September 30, 2012 During the nine months ended September 30, 2013 and 2012, we did not recognize any revenues from our operations. We do not expect to recognize revenues in the near future, as we work to complete our proposed acquisition with GIWS, discussed above. During the nine months ended September 30, 2013, we incurred general and administrative expenses of $868,209 compared to $50,259 during the nine months ended September 30, 2012. The increase of $151,950 was a result of increase of $163,250 in consulting expenses, offset by an $11,511 in professional fees. The increase of $829,250 increase in consulting expenses was a result of activities in connection with the GIWS acquisition, including a $8000,000 non-cash expense for a total of 2,000,000 shares of common stock issued to shareholders and the Company's sole officer and director in connection with their acquisition efforts. During the nine months ended September 30, 2013, we incurred a net loss of $1,028,012, compared to $134,399 during the nine months ended September 30, 2012. The increase of $893,613 is a result of the $868,209 increase in general and administrative expenses combined with a $75,663 increase in other income (expense) resulting from the $73,075 finance cost recognized in connection with $79,000 in convertible promissory notes issued by the Company during the nine months ended September 30, 2013 and an increase of $2,588 in interest expense resulting from the increase in convertible promissory notes. LIQUIDITY --------- We have nominal cash of $1,883 and no other liquid assets at September 30, 2013, and we will be reliant upon shareholder loans or private placements of equity to fund any kind of operations. We have secured no sources of loans or private placements at this time. At September 30, 2013, we had total current liabilities $2,004,836, consisting of $392,203 in accounts payable, $894,997 in accrued expense, $50,004 in advances payable, $31,632 notes payable and $699,000 in convertible notes payable. During the nine months ended September 30, 2013, we used funds of $63,432 in our operational activities. During the nine months ended September 30, 2013, we recognized a net loss of $1,028,012, which was adjusted for the $73,075 finance cost incurred in connection with the Company's issuance of $79,000 in convertible promissory notes during the nine months ended September 30, 2013 and a $800,000 non-cash expense related to the issuance of 2,000,000 shares of common stock for services. During the nine months ended September 30, 2012, we did used cash of $5,780 in our operational activities. During the nine months ended September 30, 2012, we recognized a net loss of $134,399 and did not have any non-cash adjustments to net losses. During the nine months ended September 30, 2013 and 2012, we did not use or receive any funds from investment activities. During the nine months ended September 30, 2013, we received funds of $65,175 from our financing activities. During the nine months ended September 30, 2012, we received funds of $5,850 from our financing activities. In March 2013, the Company issued an unsecured convertible promissory note in exchange for cash of $44,000. In addition, the Company issued an unsecured convertible promissory note in exchange for already outstanding advances of $25,000. The convertible promissory notes have a term of 1 year, an interest rate of 8% per annum and provides for the conversion of the note into shares of the Company's common stock at $0.07 per share. The Company has recognized a finance cost of $69,000 in connection with the convertible promissory notes. 17 In September 30, 2013, the Company issued an unsecured convertible promissory note in exchange for cash of $10,000. The convertible promissory note has a term of 3 years, an interest rate of 8% per annum and provides for the conversion of the note into shares of the Company's common stock at $0.40 per share. The Company has recognized a finance cost of $14,075 in connection with the convertible promissory notes. Short Term. On a short-term basis, Legacy has not generated any revenue or revenues sufficient to cover operations. For short term needs the Company will be dependent on receipt, if any, of offering proceeds. Capital Resources The Company has only common stock as its capital resource. Legacy has no material commitments for capital expenditures within the next year, however if operations are commenced, substantial capital will be needed to pay for participation, investigation, exploration, acquisition and working capital. Need for Additional Financing Legacy does not have capital sufficient to meet its cash needs. The Company will have to seek loans or equity placements to cover such cash needs. Once a business acquisition is completed, the Company's needs for additional financing is likely to increase substantially. No commitments to provide additional funds have been made by the Company's management or other stockholders. Accordingly, there can be no assurance that any additional funds will be available to Legacy to allow it to cover the Company's expenses as they may be incurred. ITEM 3. QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Not Applicable ITEM 4. CONTROLS AND PROCEDURES The Company maintains a system of disclosure controls and procedures that are designed for the purposes of ensuring that information required to be disclosed in the Company's SEC reports is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to the Company's management, including the Chief Executive Officer as appropriate to allow timely decisions regarding required disclosure. Management, after evaluating the effectiveness of the Company's disclosure controls and procedures as defined in Exchange Act Rules 13a-14(c) as of September 30, 2013 (the "Evaluation Date") concluded that as of the Evaluation Date, the Company's disclosure controls and procedures were effective to ensure that material information relating to the Company would be made known to them by individuals within those entities, particularly during the period in which this annual report was being prepared and that information required to be disclosed in the Company's SEC reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. 18 MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING. Legacy's management is responsible for establishing and maintaining adequate internal control over financial reporting for the company in accordance with as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company's assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that the Company's receipts and expenditures are being made only in accordance with authorizations of Legacy's management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on Legacy's financial statements. Management's assessment of the effectiveness of the registrant's internal control over financial reporting is as of September 30, 2013. The Company believes that internal control over financial reporting is ineffective, due to a lack of accounting staff. The Company does not have the financial ability to hire additional accounting staff, at this time. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. This report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report. There was no change in the Company's internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2012, that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting. PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS NONE. ITEM 1A. RISK FACTORS Not Applicable to Smaller Reporting Companies. 19 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS During the period of July 1, 2013 through September 30, 2013, the Company made the following unregistered issuances of its equity securities.

Exemption From Registration Claimed All of the above sales by the Company of its unregistered securities were made by the Company in reliance upon Section 4(2) of the Securities Act of 1933, as amended (the "1933 Act"). All of the individuals and/or entities that purchased the unregistered securities were primarily existing shareholders, known to the Company and its management, through pre-existing business relationships, as long standing business associates and existing shareholders. All purchasers were provided access to all material information, which they requested, and all information necessary to verify such information and were afforded access to management of the Company in connection with their purchases. All purchasers of the unregistered securities acquired such securities for investment and not with a view toward distribution, acknowledging such intent to the Company. All certificates or agreements representing such securities that were issued contained restrictive legends, prohibiting further transfer of the certificates or agreements representing such securities, without such securities either being first registered or otherwise exempt from registration in any further resale or disposition. ITEM 3. DEFAULTS UPON SENIOR SECURITIES NONE. ITEM 4. MINE AND SAFETY DISCLOSURE Not Applicable ITEM 5. OTHER INFORMATION NONE. 20 ITEM 6. EXHIBITS Exhibits. The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K. Exhibit 31.1 Certification of Chief Executive Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act Exhibit 32.1 Certification of Principal Executive and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act 21 SIGNATURES Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGACY TECHNOLOGY HOLDINGS, INC. (Registrant) Dated: March __, 2014 By: /s/ Redgie Green -------------------------------- Redgie Green (Principal Executive Officer, President and Chief Executive Officer)

Filing Compare · LEGACY TECHNOLOGY HOLDINGS, INC.